Is KALA Worth Buying in 2026?

KALA BIO, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-05-03

Here’s whether KALA BIO, Inc. Common Stock (KALA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-18.22% over 10 days); RSI 11 — oversold; weak 1-year return of -97.1%; 3-month momentum negative (-79.3%); rising volume on a downtrend (distribution, 1.28x avg). Currently 99.5% off its 52-week high. Score: -7/7.

Ready to act on this? 📈 Trade on Webull

KALA is trading below its 200-day MA ($3.30) — a key warning sign the longer-term trend is under pressure. An RSI of 10.8 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -97.1% compares to +27.9% for SPY (trailed the market by 125.0%). The current 99.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $293 today
vs. S&P 500 (SPY) — same period trailed market by 125.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($3.30)
Above 50-day MA ($0.24)
!RSI(14) neutral zone (30–70) — currently 10.8
Positive return (-97.1%)
!Within 10% of period high (−99.5%)
Period Range $0.11
$0.10 $20.60
RSI (14) 10.8
0 · OversoldOverbought · 100

Key Metrics

Price$0.11
Period Return-97.1%
Period High$20.60
Period Low$0.10
Drawdown−99.5%
MA-50$0.24
MA-200$3.30
RSI (14)10.8
Avg Volume (30d)3.4M
vs. SPYtrailed by 126.1%
Return Rank#1212 of 1236

Trade KALA

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers